1459754-39-2

Usage

Uses

Used in Medicinal Chemistry:
(2-chloro-5-iodophenyl)(4-methoxyphenyl)methanone is used as a potential candidate in medicinal chemistry for its possible biological activities. (2-chloro-5-iodophenyl)(4-methoxyphenyl)methanone's methanone derivative nature suggests it may possess antimicrobial, antifungal, and anti-inflammatory properties, which are valuable for the development of new pharmaceuticals.
Used in Organic Synthesis:
In the field of organic synthesis, (2-chloro-5-iodophenyl)(4-methoxyphenyl)methanone is utilized for its reactivity, which may be enhanced by the halogen substitution on the phenyl groups. This characteristic makes it a useful intermediate or reactant in the synthesis of other complex organic molecules.
Used in Research and Development:
(2-chloro-5-iodophenyl)(4-methoxyphenyl)methanone serves as a subject of study in research and development for understanding its physical and chemical properties. Detailed investigation could reveal further insights into its potential applications, including its behavior in various chemical reactions and its interactions with biological systems.

Upstream product

• 19094-56-5 2-chloro-5-iodobenzoic acid 
• 281652-58-2 2-chloro-5-iodobenzoylchloride 
• 100-66-3 methoxybenzene 

Downstream Products

• 864070-37-1 (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-hydroxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1459754-40-5 (2-chloro-5-iodophenyl)(4-hydroxyphenyl)methanone 
• 864070-44-0 empagliflozin 
• 1459754-36-9 2-(4-methoxybenzyl)-1-chloro-4-iodobenzene 
• 912917-83-0 (3R,4S,5S,6R)-2-(4-chloro-3-(4-hydroxybenzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol 
• 1459754-32-5 4-(2-chloro-5-iodobenzyl)phenol 
• 1400980-44-0 1-chloro-2-(4-(2-cyclopropoxyethoxy)benzyl)-4-iodobenzene 

Relevant academic research and scientific papers

SOLID STATE FORMS OF EMPAGLIFLOZIN

The present invention provides solid state forms of empagliflozin, complexes of empagliflozin with amino acids, processes for their preparation and their use in purification of empagliflozin and also provided pharmaceutical compositions comprising them and their use in therapy (Formula I).

OPTICALLY PURE BENZYL-4-CHLOROPHENYL-C-GLUCOSIDE DERIVATIVE

The present invention relates to a pharmaceutical technology, and more specifically, to optically pure benzyl-4-chloro-phenyl glucoside derivatives represented by the chemical formula II and III or a pharmaceutically acceptable salt thereof. The present invention also relates to a method for preparing the compounds and intermediates thereof, pharmaceutical formulations and pharmaceutical compositions containing the compounds, and the use of the optically pure benzyl-4-chloro-phenyl glucoside derivatives as sodium glucose co-transporter (SGLT) inhibitors for the prevention and treatment of the diabetes including the insulin dependent diabetes mellitus and non-insulin dependent diabetes mellitus and the diabetes-related deseases such as insulin-resistant diseases and obesity.COPYRIGHT KIPO 2015

PREPARATION OF HYDROXY-BENZYLBENZENE DERIVATIVES

Methods for preparing intermediates of SGLT2 inhibitors are provided, including crystalline forms and methods of crystallizing intermediates.

OPTICALLY PURE BENZYL-4-CHLOROPHENYL-C-GLUCOSIDE DERIVATIVE

The present invention belongs to the field of pharmaceutical technology, more specifically relates to optically pure benzyl-4-chlorophenyl-C-glucoside derivatives represented by formulae (II) and (III), a process for preparing these compounds and intermediates thereof, a pharmaceutical formulation and a pharmaceutical composition containing these compounds, and the use of the optically pure benzyl-4-chlorophenyl-C-glucoside derivative as a sodium glucose co-transporter (SGLT) inhibitor in manufacture of a medicament for treating and/or preventing diabetes mellitus (including insulin-dependent diabetes mellitus and non-insulin-dependent diabetes mellitus) or diabetes-associated diseases (including insulin resistance disease and obesity)

Optically pure benzyl-4-chlorophenyl-C-glucoside derivatives as SGLT inhibitors (diabetes mellitus)

The present invention belongs to the field of pharmaceutical technology, more specifically relates to optically pure benzyl-4-chlorophenyl-C-glucoside derivatives represented by formulae (II) and (III), a process for preparing these compounds and intermediates thereof, a pharmaceutical formulation and a pharmaceutical composition containing these compounds, and the use of the optically pure benzyl-4-chlorophenyl-C-glucoside derivative as a sodium glucose co-transporter (SGLT) inhibitor in manufacture of a medicament for treating and/or preventing diabetes mellitus (including insulin-dependent diabetes mellitus and non-insulin-dependent diabetes mellitus) or diabetes-associated diseases (including insulin resistance disease and obesity) or

PREPARATION OF HYDROXY-BENZYLBENZENE DERIVATIVES

Methods for preparing intermediates of SGLT2 inhibitors are provided, including crystalline forms and methods of crystallizing intermediates.